



#20

Sheet 1 of 5

Form PTO-1449 Modified		Docket No. CELL-0086 (PA 446.3)	Serial No. 09/450,999
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant John Robert Porter, et al.	
		Filing Date November 29, 1999	Group 1624
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
T24	AA	Alhaique, F., et al., "Cyclisation of dinitriles by sodium alkoxides a new synthesis of naphthyridines," <i>Tetrahedron Letters</i> , 1975 , 3, 173-174	
74	AB	Ames, D.E., et al., "Condensation of β -dicarbonyl compounds with halogenopyridinecarb-oxylic acids. A convenient synthesis of some naphthyridine derivatives," <i>J.C.S. Perkin I</i> , 1972 , 705-710	
81	AC	Bodor, N., "Novel approaches in prodrug design," <i>Alfred Benzon Symposium</i> , 1982 , 17, 156-177	
92	AD	Brooks, Peter C., et al., "Antiintegrin $\alpha\beta 3$ blocks human breast cancer growth and angiogenesis in human skin," <i>J. Clin. Invest.</i> , 1995 , 96, 1815-1822	
*	AE	Bundgaard, H., <i>Design of Prodrugs</i>, 1985, Elsevier, Amsterdam	
*	AF	Katritzky, A.R., et al (Eds.), <i>Comprehensive Organic Functional Group Transformations</i>, Pergamon, 1995	
92	AG	Davies, S.G., et al., "Asymmetric synthesis of R- β -amino butanoic acid and S- β -tyrosine: homochiral lithium amide equivalents for Michael additions to α, β -unsaturated esters," <i>Tetra. Asymmetry</i> , 1991 , 2(3), 183-186	
92	AH	Erle, D.J., et al., "Expression and function of the MadCAM-1 receptor, integrin $\alpha 4 \beta 7$, on human leukocytes," <i>J. Immunol.</i> , 1994 , 153, 517-528	
*	AI	Encyclopedia of Reagents for Organic Synthesis, <i>John Wiley and Sons (eds.)</i>, 1995	
T24	AJ	Giacomello, et al., "Synthesis of 2,6-naphthyridine," <i>Tetra. Letters</i> , 1965 , 16, 1117-1121	
EXAMINER		DATE CONSIDERED 3/14/02	

* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0086 (PA 446.3)	Serial No. 09/450,999
	Applicant John Robert Porter, et al.	
	Filing Date November 29, 1999	Group 1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*	AK	Green, T.W., et al., "Protective Groups in Organic Synthesis," <i>John Wiley and Sons</i> (eds.), 1991
	AL	Hammes, H., et al., "Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization," <i>Nature Medicine</i> , 1996, 2, 529-533
	AM	Hodivala-Dilke, K.M., "β3-integrin-deficient mice are a model for glanzmann thrombasthenia showing placental defects and reduced survival," <i>J. Clin. Invest.</i> , 1999, 103(2), 229-238
	AN	Kalvin, D.M., et al., Synthesis of (4R)-D,L-[4- ² H]- and (4S)-D,L-[4- ² H] homoserine lactones," <i>J. Org. Chem.</i> , 1985, 50, 2259-2263
	AO	Koivunen, E., et al., "Selection of peptides binding to the α ₅ β ₁ integrin from phage display library," <i>J. Biological Chemistry</i> , 1993, 268(27), 20205-20210
	AP	Mitjans, F., et al., "An anti-αv-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice," <i>J. Cell Science</i> , 1995, 108, 2825-2838
	AQ	Molina, P., et al., "Iminophosphorane-mediated annelation of a pyridine ring into a preformed pyridine one: synthesis of naphthyridine, pyrido [1,2-c] pyrimidine and pyrido [1,2-c] quinazoline derivatives," <i>Tetrahedron</i> , 1992, 48(22), 4601-4616
	AR	Newham, P., et al., "Integrin adhesion receptors: structure, function and implications for biomedicine," <i>Molecular Medicine Today</i> , 1996, 304-313
	AS	Numata, A., et al., "General synthetic method for naphthyridines and their N-oxides containing isoquinolinic nitrogen," <i>Synthesis</i> , 1999, 2, 306-311
	AT	Sakamoto, T., et al., "Condensed heteroaromatic ring systems. III. synthesis of naphthyridine derivatives by cyclization of ethynylpyridinecarboxamides," <i>Chem. Pharm. Bull.</i> 1985, 33(2), 626-633
EXAMINER <i>John O'Malley</i>		DATE CONSIDERED <i>3/14/02</i>

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office Since it is believed to be too voluminous and easily obtainable by the Examiner

**Form PTO-1449 Modified**

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.
CELL-0086
(PA 446.3)

Serial No.
09/450,999

Applicant
John Robert Porter, et al.

Filing Date
November 29, 1999

Group
1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>ten</i>	AU	Singh, G., et al., "Prodrug approach in new drug design and development," <i>J. Sci. Ind. Res.</i> , 1996, 55, 497-510
	AV	Srivatsa, S.S., et al., "Selective $\alpha\beta_3$ integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin $\alpha\beta_3$ and osteopontin expression during neointima formation," <i>Cardiovascular Research</i> , 1997, 36, 408-428
	AW	Stupack, D.G., et al., "induction of $\alpha\beta_3$ integrin-mediated attachment to extracellular matrix in B_1 integrin (CD29)-negative B cell lines," <i>Experi. Cell Research</i> , 1992, 203, 443-448
	AX	Tan R., et al., "Synthesis of 2, 6-naphthyridine and some of its derivatives," <i>Tetrahedron Letters</i> , 1965, 31, 2737-2744
	AY	Rico, J.G., et al., "A highly stereoselective michael addition to an $\alpha\beta$ -unsaturated ester as the crucial step in the synthesis of a novel β -amino acid-containing fibrinogen receptor antagonist," <i>J. Org. Chem.</i> , 1993, 58, 7948-7951
<i>↓</i>	AZ	Zablocki, J.A., "Potent <i>in vitro</i> and <i>in vivo</i> inhibitors of platelet aggregation based upon the arg-gly-asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists," <i>J. Med. Chem.</i> , 1995, 38, 2378-2394
EXAMINER	<i>John R. Porter</i>	
	DATE CONSIDERED	<i>3/14/02</i>

**Form PTO-1449 Modified**

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.
CELL-0086
(PA 446.3)

Serial No.
09/450,999

Applicant
John Robert Porter, et al.

Filing Date
November 29, 1999

Group
1624

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
TEN	BA	WO 97/04247	02/06/97	PCT		
	BB	WO 97/23480	07/03/97	PCT		
	BC	WO 97/36858	10/09/97	PCT		
	BD	WO 97/36861	10/09/97	PCT		
	BE	WO 97/36862	10/09/97	PCT		
	BF	WO 97/44333	11/27/97	PCT	X Abstract	
	BG	WO 98/18460	05/07/98	PCT		
	BH	WO 98/25892	06/18/98	PCT		
	BI	WO 98/31359	07/23/98	PCT		
	BJ	WO 99/26921	06/03/99	PCT		
	BK	WO 99/26922	06/03/99	PCT		
	BL	WO 99/26945	06/03/99	PCT		
	BM	WO 99/31061	06/24/99	PCT		
	BN	WO 99/31099	06/24/99	PCT		
	BO	WO 99/32457	07/01/99	PCT		
	BP	WO 99/36393	07/22/99	PCT		
	BQ	WO 99/44994	09/10/99	PCT		
	BR	WO 99/52879	10/21/99	PCT		
	BS	WO 99/52896	10/21/99	PCT		
	BT	WO 99/52898	10/21/99	PCT		

EXAMINER**DATE CONSIDERED** 3/14/02



Form PTO-549 Modified

Docket No.
CELL-0086
(PA 446.3)Serial No.
09/450,999List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)Applicant
John Robert Porter, et al.U.S. Department of Commerce
Patent and Trademark OfficeFiling Date
November 29, 1999Group
1624**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
jm	BU	WO 99/60015	11/25/99	PCT	X Abstract	
	BV	WO 99/64395	12/16/99	PCT		
	BW	WO 99/67230	12/29/99	PCT		
	BX	WO 00/00486	01/06/00	PCT		
	BY	WO 00/01383	01/13/00	PCT		
	BZ	WO 00/06169	02/10/00	PCT		
	CA	WO 00/07544	02/17/00	PCT		
	CB	WO 00/17197	03/30/00	PCT		
V	CC	WO 00/23419	04/27/00	PCT		
EXAMINER <i>Sam Miller</i>				DATE CONSIDERED <i>3/14/02</i>		